ANI News ‘Major side-effects…” Dr. V. Mohan discusses health risks of anti-obesity GLP-1 drugs

The content discusses the discovery and impact of GLP-1 receptor agonists, particularly semaglutide, a hormone-based drug that significantly aids in weight reduction and diabetes management. Originally available as an oral tablet, the injectable form of semaglutide recently entered the Indian market, leading to a surge in its availability and a significant drop in price due to the expiration of its patent. This has resulted in widespread advertising and over-prescription by non-medical professionals, prompting the DCGI to issue warnings about its misuse. While semaglutide offers substantial benefits, including reduced HbA1c levels, decreased liver fat, and reduced cravings, it also carries serious potential side effects such as blindness, thyroid cancer, and pancreatitis. Therefore, it should only be prescribed and managed by qualified medical professionals. Social media often misrepresents the drug’s effects, failing to mention that weight regain is common after discontinuing use. Long-term commitment to the medication is essential, as stopping and restarting can lead to diminished effectiveness and potential side effects. The content emphasizes the need for strict medical supervision and accurate information dissemination to ensure safe and effective use of semaglutide.

#Semaglutide #Ozempic #Wegovy #GLP1 #WeightLossDrugs #DiabetesCare #HealthNews #IndiaNews #DCGI #DrugSafety #MedicalNews #Obesity #FitnessIndia #HealthAlert #PharmaNews #BreakingNews #SideEffects #DoctorAdvice #Healthcare #TrendingNews #YouTubeShorts

Join ANI’s YouTube membership to get access to perks:
https://www.youtube.com/channel/UCtFQDgA8J8_iiwc5-KoAQlg/join

Subscribe now and press the bell icon 🔔 to get new video updates: https://bit.ly/2UV4ygi
————————————–
ANI is South Asia’s leading Multimedia News Agency providing content for every information platform, including TV, Internet, broadband, newspapers, and mobiles.
Subscribe now! Enjoy and stay connected with us!!
☛ Subscribe to ANI News YouTube channel: https://bit.ly/2UV4ygi
☛ Visit our Official website: https://www.aninews.in/
☛ Follow ANI: https://twitter.com/ANI
☛ Follow us on Snapchat: https://www.snapchat.com/@ani-news
☛ Like us: https://www.facebook.com/ANINEWS.IN
☛ Email to: anicontent@aniin.com, internetani@aniin.com
☛ Instagram: https://www.instagram.com/ani_trending/ , https://www.instagram.com/podcast_ani/?hl=en
☛ Copyrights © All Rights Reserved ANI Media Pvt Ltd.

Watch the full video on YouTube